Verrica Pharmaceuticals Inc (NAS:VRCA)
$ 0.6843 0.0356 (5.49%) Market Cap: 61.97 Mil Enterprise Value: 82.90 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 14, 2022 / 07:30PM GMT
Release Date Price: $3.91 (+0.77%)
Oren Livnat
H.C. Wainwright & Co. - Managing Director of Equity Research

Good afternoon. Thank you for joining us at the H.C. Wainwright 24th Annual Global Investment hybrid conference. My name is Oren Livnat. I'm specialty pharmaceuticals analyst here at H.C. Wainwright. And it's my pleasure to welcome for a brief chat today Ted White, CEO and President of Verrica Pharmaceuticals. I do cover Verrica with a buy rating. So afterwards and separately, feel free to reach out to me with any questions.

Verrica is a medical dermatology-focused company with a lead asset, VP-102, a topical cantharidin drug device combination to treat molluscum contagiosum lesions. It's a highly prevalent contagious condition with no FDA-approved treatments.

And exciting times, Verrica's in the homestretch, already under FDA review, and we expect approval next year. So it's about to be a commercial story and right in my spec pharma wheelhouse. So, Ted, welcome.

Ted White
Verrica Pharmaceuticals Inc. - President & CEO

Thank you, Oren. Good to be with you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot